Bioasis Technologies announced a joint research collaboration with a leading pharmaceutical company.
Under the terms of the Agreement, Bioasis will manufacture an antibody-peptide conjugate containing Bioasis’ xB3 peptide for in vivo measurement in the CNS, enabling direct evaluation of the xB3 platform’s delivery capabilities.
“We are excited to be working with a leading global biopharmaceutical company with an extensive track record of successfully bringing forward innovative new therapies. Entering into this research collaboration is a significant step forward in the validation of our xB3 platform technology, and more information about this collaboration may be made available as the research progresses,” said Mark Day, Ph.D., director, president and chief executive officer. “This research collaboration provides Bioasis the opportunity to work with another premier scientific partner in addition to Prothena and further supports our efforts to positively impact disease modification of devastating neurological diseases.”